Key result
Increased myocardial T2 (HR 1.14) and quantified late gadolinium enhancement (HR 1.07) on cardiac MRI were independently associated with major adverse cardiovascular events in patients with chemotherapy-related cardiac dysfunction.
Why the study?
To quantitatively analyze the CMR characteristics of chemotherapy-related cardiac dysfunction and explore their prognostic value for MACE.
Do quantitative CMR parameters predict major adverse cardiovascular events in patients with chemotherapy-related cardiac dysfunction?
Cohort (n=145)
No
Do quantitative CMR parameters predict major adverse cardiovascular events in patients with chemotherapy-related cardiac dysfunction?
Hazard Ratio: 1.14 (95% CI 1.01–1.27)
p-value: p=0.028
Quantitative CMR parameters, specifically T2 mapping and LGE quantification, are independent predictors of major adverse cardiovascular events in patients with chemotherapy-related cardiac dysfunction.
May aid risk stratification in chemotherapy-related cardiac dysfunction; supports prospective validation of cardiac MRI parameters.
OBJECTIVE: To quantitatively analyze the cardiac magnetic resonance imaging (CMR) characteristics of chemotherapy-related cardiac dysfunction (CTRCD) and explore their prognostic value for major adverse cardiovascular events (MACE). MATERIALS AND METHODS: A total of 145 patients (male:female = 76:69, mean age = 63.0 years) with cancer and heart failure who underwent CMR between January 2015 and January 2021 were included. CMR was performed using a 3T scanner (Siemens). Biventricular functions, native T1 T2, extracellular volume fraction (ECV) values, and late gadolinium enhancement (LGE) of the left ventricle (LV) were compared between those with and without CTRCD. These were compared between patients with mild-to-moderate CTRCD and those with severe CTRCD. Cox proportional hazard regression analysis was used to evaluate the association between the CMR parameters and MACE occurrence during follow-up in the CTRCD patients. RESULTS: = 0.021) were independently associated with MACE in the CTRCD patients. CONCLUSION: Quantitative parameters from CMR have the potential to evaluate myocardial changes in CTRCD. Increased T2 with reduced LV mass was demonstrated in CTRCD patients even before the development of severe cardiac dysfunction. T2 and quantified LGE may be independent prognostic factors for MACE in patients with CTRCD.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2023) conducted a cohort in Chemotherapy-related cardiac dysfunction (CTRCD) (n=145). Myocardial T2 mapping vs. Lower T2 values was evaluated on Major adverse cardiovascular events (MACE) (HR 1.14, 95% CI 1.01-1.27, p=0.028). Increased myocardial T2 (HR 1.14) and quantified late gadolinium enhancement (HR 1.07) on cardiac MRI were independently associated with major adverse cardiovascular events in patients with chemotherapy-related cardiac dysfunction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: